Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.chinooktx.com
Global Number of Employees (Latest): 214
Year Founded: 2015
Total Amount Raised (CAD mm)†: 238.89
Total Rounds of Funding**:3
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company’s lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company was formerly known as Chinook Therapeutics U.S., Inc. and changed its name to Chinook Therapeutics, Inc. in October 2020. Chinook Therapeutics, Inc. was incorporated in 2015 and is headquartered in Seattle, Washington with additional location in Vancouver, Canada and Oakland, California. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.

Financial Information (Currency: CAD, in mm) 
Total Revenue
8.0
Market Capitalization
3,984.2
TEV/Total Revenue
NM
EBITDA
(313.3)
Total Enterprise Value
3,619.9
TEV/EBITDA
NM
EBIT
(321.3)
Cash & ST Invst.
408.2
P/Diluted EPS Before Extra
NM
Net Income
(337.5)
Total Debt
46.7
Price/Tang BV
9.1x
Capital Expenditure
(3.6)
Total Assets
671.5
Total Debt/EBITDA
NM
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Aug-10-2023

Key Professionals
Name
Title
Thethy, Sukhi 
Senior Vice President of Finance & Accounting
Liffick, Noopur Batsha
Senior Vice President of Investor Relations & Corporate Communications
Fauvelle, Valerie 
Senior Vice President of Regulatory Affairs
Glicklich, Alan 
Executive Officer
Imbert, Delphine 
Senior Vice President of CMC & Technical Operations
Jones-Burton, Charlotte 
Senior Vice President of Product Development & Strategy


Primary Industry Classification
Biotechnology


Primary Office Location
400 Fairview Avenue North Suite 900 | Seattle, WA | 98109 | United States
Phone: 206 485 7241   

Parent Company
Novartis AG (SWX:NOVN)

Prior Investors
AbbVie Ventures, Inc., Ally Bridge Group, Apple Tree Partners, Apple Tree Partners IV, L.P., Avidity Partners Management, L.P., BlackRock, Inc. (NYSE:BLK), Citadel Advisors LLC, Citadel Multi-Strategy Equities Master Fund Ltd., EcoR1 Capital, LLC, Fidelity Management & Research Company LLC, Frazier Life Sciences Management, LP, Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences X, L.P., Frazier Management, L.L.C. (Albert Cha, James Brush), HBM Healthcare Investments AG (SWX:HBMN), HBM Partners Ltd., Janus Henderson Group plc (NYSE:JHG), Monashee Investment Management, LLC, Northleaf Capital Partners Ltd., OrbiMed Advisors LLC, Rock Springs Capital Management LP, Samsara BioCapital LLC, Samsara Biocapital, L.P., Sphera Biotech Master Fund L.P., Sphera Funds Management Ltd, Versant Venture Capital VIII, L.P., Versant Venture Management, LLC, Versant Voyageurs I LP, Versant Voyageurs I Parallel, L.P.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Aduro Biotech, Inc.
As of October 5, 2020, Aduro Biotech, Inc. was acquired by Chinook Therapeutics Inc., in a reverse merger transaction. Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body’s natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; and license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro Biotech, Inc. in June 2008. Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

United States and Canada
Biotechnology
28.00
265.00
33.00
Aduro Biotech Europe
Aduro Biotech Europe, a clinical-stage cancer immunotherapy company, is engaged in the discovery, development, and commercialization of a pipeline of novel immunotherapies for various cancer types. It develops live, attenuated, and double-deleted Listeria mononcytogenes; and STING-targeted Cyclic dinucleotides platforms, and B-select monoclonal antibodies. The company also provides GVAX Pancreas for patients with metastatic pancreatic cancer. Aduro Biotech Europe was formerly known as BioNovion B.V. and changed its name to Aduro Biotech Europe. As a result of the acquisition BioNovion has been renamed as Aduro Biotech Europe. The company is based in Oss, the Netherlands. It was incorporated in 2011 and is headquartered in Oss, Netherlands. Aduro Biotech, Europe B.V. was incorporated in 2011 and is headquartered in Rosmalen, Netherlands. Aduro Biotech Europe operates as a subsidiary of Chinook Therapeutics, Inc.

Europe
Biotechnology
-
-
-
Aduro Biotech Holdings, Europe B.V.
Aduro Biotech Holdings, Europe B.V. was incorporated in 2011 and is headquartered in Rosmalen, Netherlands.

Europe
-
-
-
-
Aduro Netherlands Coöperatief U.A.
Aduro Netherlands Coöperatief U.A. is based in the Netherlands. Aduro Netherlands Coöperatief Ua is a holding, patent owners, and trusts or estates company. It operates as a holding company. It was incorporated in 2015 and is headquartered in Oss, Netherlands. Aduro Netherlands Coöperatief U.A. operates as a subsidiary of Chinook Therapeutics, Inc.

Europe
Multi-Sector Holdings
-
-
-
Chinook Therapeutics Canada Inc.
Chinook Therapeutics Canada, Inc. operates as a subsidiary of Chinook Therapeutics, Inc. 

United States and Canada
-
-
-
-
Chinook Therapeutics U.S Inc.
Chinook Therapeutics U.S, Inc. operates as a subsidiary of Chinook Therapeutics, Inc.

United States and Canada
-
5.00
-
-
Plus Therapeutics, Inc. (NasdaqCM:PSTV)
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

United States and Canada
Biotechnology
3.00
14.00
5.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-12-2023
Aug-11-2023
Merger/Acquisition
Target
Chinook Therapeutics, Inc.
Novartis AG (SWX:NOVN)
Versant Venture Management, LLC,Apple Tree Partners,Samsara BioCapital LLC,OrbiMed Advisors LLC,Ally Bridge Group,Northleaf Capital Partners Ltd.,Frazier Management, L.L.C.,Frazier Life Sciences Management, LP,BlackRock, Inc. (NYSE:BLK) Seller Funds:Samsara Biocapital, L.P., Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences X, L.P.
3,498.91
Feb-27-2023
Aug-11-2023
Shelf Registration
Target
Chinook Therapeutics, Inc.


73.21
Nov-10-2022
Aug-11-2023
Shelf Registration
Target
Chinook Therapeutics, Inc.


32.93
May-24-2022
May-24-2022
Public Offering
Target
Chinook Therapeutics, Inc.


105.00
May-24-2022
-
Shelf Registration
Target
Chinook Therapeutics, Inc.


-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-11-2023
Changes in Company Bylaws/Rules
Chinook Therapeutics, Inc. Amends and Restates Certificate of Incorporation and Bylaws
Aug-11-2023
Executive/Board Changes - Other
Chinook Therapeutics, Inc. Announces Board Cessations
Aug-11-2023
Shelf Registration Filings
Chinook Therapeutics, Inc. has closed its Shelf Registration dated March 01, 2017 in the amount of $38.203999 million.
Aug-11-2023
Shelf Registration Filings
Chinook Therapeutics, Inc. has closed its Shelf Registration dated March 09, 2020 in the amount of $10.398755 million.
Aug-11-2023
Shelf Registration Filings
Chinook Therapeutics, Inc. has closed its Shelf Registration dated March 01, 2018 in the amount of $19.43405 million.

M&A Advisors
Centerview Partners LLC, Fenwick & West LLP, MTS Health Partners, L.P.


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Centerview Partners LLC, Fenwick & West LLP, MTS Health Partners, L.P.
Private Placement Advisors
Evercore Group L.L.C., Leerink Partners LLC, William Blair & Company, L.L.C.
Public Offering Advisors
Deloitte & Touche LLP, Fenwick & West LLP, Latham & Watkins LLP, PricewaterhouseCoopers LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 05:49 AM
Chinook Therapeutics, Inc.
Chinook Therapeutics Inc (KDNY.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
100
Evercore ISI
Chen, Jingming
Sep 14, 2023 02:53 PM
Chinook Therapeutics, Inc.
Dropping Coverage
Reports
7
GlobalData

Sep 12, 2023 03:59 AM
Chinook Therapeutics, Inc.
Chinook Therapeutics Inc (KDNY.NASD) - Financial Analysis Review
Reports
322
Marktfeld
Paraskevopoulos, Michail
Sep 05, 2023 12:14 AM
Chinook Therapeutics, Inc.
Chinook Therapeutics Inc: Information Content of Earnings Releases 2018-2023
Reports
4
Stifel
Thompson, Alexander
Aug 18, 2023 02:32 PM
Chinook Therapeutics, Inc.
Discontinuing Coverage
EPS Estimates*
5
The Economy Matters

Aug 14, 2023 04:29 AM
Chinook Therapeutics, Inc.
The Economy Matters
Reports
8
H.C. Wainwright & Co.
Arce, Antonio Eduardo
Aug 14, 2023 03:55 AM
Chinook Therapeutics, Inc.
KDNY: Acquisition by Novartis Closed; Dropping Coverage
Ratings Change*
7
Wells Fargo Securities, LLC
Bansal, Mohit
Aug 13, 2023 06:59 PM
Chinook Therapeutics, Inc.
KDNY: Dropping Coverage
Reports
5
Piper Sandler Companies
Rahimi, Yasmeen
Aug 13, 2023 06:33 PM
Chinook Therapeutics, Inc.
Discontinuing Coverage
EPS Estimates*
4
Wedbush Securities Inc.
Chico, Laura Kathryn
Aug 12, 2023 05:13 AM
Chinook Therapeutics, Inc.
Dropping Coverage of KDNY
Reports
4


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


BlackRock, Inc.

2,324,517

3.24

126.4

Jul-31-2023


Teachers Insurance and Annuity Association-College Retirement Equities Fund

238,335

0.33

13.0

Aug-31-2023


The Vanguard Group, Inc.

128,979

0.18

7.0

Aug-31-2023


ALPS Advisors, Inc.

20,700

0.03

1.1

Aug-31-2023


Nationwide Fund Advisors

485

0.00

0.0

Jul-31-2023


L2 Asset Management, LLC

104

0.00

0.0

Jul-31-2023


Wespath Institutional Investments Llc

92

0.00

0.0

Jul-31-2023


Simplify Asset Management Inc.

0

0.00

0.0

Oct-05-2023


Two Sigma Securities, LLC, Asset Management Arm

0

0.00

0.0

Oct-05-2023


Water Island Capital, LLC

0

0.00

0.0

Oct-05-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
L2 Asset Management, LLC
104
15

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Samsara BioCapital LLC
0
(5,161,888)
Frazier Life Sciences Management, LP
0
(4,345,559)
Versant Venture Management, LLC
0
(3,035,207)
Deep Track Capital, LP
0
(3,000,000)
State Street Global Advisors, Inc.
0
(2,907,317)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-12
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
ENP Newswire


Company Coverage
This company is not on any Coverage List.

Products
Atrasentan (Future), BION-1301 (Future), CHK-336 (Future), Licensing of Atrasentan, Licensing of BION-1301


Upcoming Events
Date/Time
Type
Nov-07-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Reporting Owner(s)
Source
Form Type
Size
Aug-11-2023
-
Chinook Therapeutics, Inc.

SEC
POSASR
21 KB
Aug-11-2023
-
Chinook Therapeutics, Inc.

SEC
POS AM
21 KB
Aug-11-2023
Aug-11-2023
Chinook Therapeutics, Inc.

SEC
8-K (1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01)
243 KB
Aug-11-2023
-
Chinook Therapeutics, Inc.
The NASDAQ Stock Market LLC
SEC
25-NSE
3 KB
Aug-07-2023
Jun-30-2023
Chinook Therapeutics, Inc.

SEC
10-Q
13 MB
Aug-03-2023
Aug-02-2023
Chinook Therapeutics, Inc.

SEC
8-K (5.07)
148 KB
Aug-01-2023
-
Chinook Therapeutics, Inc.

SEC
DEFA14A
19 KB
Jul-28-2023
Jul-28-2023
Chinook Therapeutics, Inc.

SEC
8-K (8.01, 9.01)
190 KB
Jul-26-2023
-
Chinook Therapeutics, Inc.

SEC
DEFA14A
108 KB
Jul-10-2023
-
Chinook Therapeutics, Inc.
Novartis Venture Funds
SEC
DFAN14A
23 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Versant Venture Management, LLC
Aug-11-2023
Common Shares
(3,035,207)
0
Sale to Issuer
(100.00)
Form 4
-
Aug-11-2023
Common Shares
(2,105,107)
0
Sale to Issuer
-
Form 4
-
Aug-11-2023
Common Shares
(719,104)
0
Sale to Issuer
-
Form 4
-
Aug-11-2023
Common Shares
(210,996)
0
Sale to Issuer
-
Form 4
Griffin MBA, Michelle  (Former Independent Director)
Aug-11-2023
Common Shares
(3,300)
0
Sale to Issuer
(100.00)
Form 4
Bjerkholt M.B.A., Eric H. (Former Chief Financial Officer)
Aug-11-2023
Common Shares
(39,371)
0
Sale to Issuer
(100.00)
Form 4
Dobmeier J.D., Eric L. (Former President, CEO & Director)
Aug-11-2023
Common Shares
(301,138)
0
Sale to Issuer
(100.00)
Form 4
Akkaraju M.D., Ph.D., Srinivas  (Former Independent Director)
Aug-11-2023
Common Shares
(3,300)
0
Sale to Issuer
(100.00)
Form 4
Excluding Automatic Transactions
Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Thethy, Sukhi 
Senior Vice President of Finance & Accounting
206 485 7241
-

Liffick, Noopur Batsha
Senior Vice President of Investor Relations & Corporate Communications
(510) 809-2465
-

Fauvelle, Valerie 
Senior Vice President of Regulatory Affairs
206 485 7241
-

Glicklich, Alan 
Executive Officer
206 485 7241
-

Imbert, Delphine 
Senior Vice President of CMC & Technical Operations
206 485 7241
-

Jones-Burton, Charlotte 
Senior Vice President of Product Development & Strategy
206 485 7241
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
